Creatv Bio, a division of Creatv MicroTech Inc., has begun collaborating with CytoDyn Inc. to deploy its LifeTracDx blood-based liquid biopsy test as an exploratory biomarker in a Phase 2 clinical study evaluating leronlimab in combination with trifluridine and tipiracil and bevacizumab in patients with relapsed or refractory metastatic colorectal cancer. The trial, registered as NCT06699836, is enrolling approximately 60 participants and will measure changes in PD-L1 expression through serial blood sampling during the treatment period.
While the announcement primarily introduces a diagnostic collaboration, the broader significance lies in how biomarker tracking may increasingly shape the development of combination immunotherapy strategies in difficult-to-treat cancers such as microsatellite-stable metastatic colorectal cancer. The use of blood-based monitoring tools like LifeTracDx reflects a growing industry effort to capture dynamic immune changes inside the tumor microenvironment without relying solely on tissue biopsies.
How liquid biopsy biomarkers could reshape immune response monitoring in metastatic colorectal cancer trials
In metastatic colorectal cancer, particularly the microsatellite-stable subtype, response rates to immunotherapy have historically been limited. Unlike tumors with high microsatellite instability, these cancers tend to exhibit immunologically “cold” microenvironments that do not readily respond to checkpoint blockade. This challenge has driven research toward strategies that can modify immune signaling pathways and potentially render tumors more responsive to immune therapies.
CytoDyn’s investigational antibody leronlimab targets the CCR5 receptor, a signaling pathway implicated in immune cell migration, tumor progression, and inflammatory regulation. By blocking CCR5, researchers hope to disrupt the tumor-supportive immune microenvironment and potentially trigger downstream immune activation.
In this context, the ability to measure immune markers such as PD-L1 in circulating tumor cells becomes particularly relevant. Industry observers note that changes in PD-L1 expression may provide early clues about whether immune activation is occurring in response to therapy, potentially offering insight long before radiographic response is visible.
LifeTracDx attempts to address this need by combining detection of circulating tumor cells with cancer-associated macrophage-like cells, which are immune cells that have engulfed tumor material. The platform’s design is intended to capture both tumor-derived and immune-derived signals, offering a window into how cancer cells and the immune system interact during therapy.
What this collaboration reveals about the increasing integration of diagnostics into oncology drug development
The collaboration between Creatv Bio and CytoDyn illustrates a broader shift in oncology clinical research. Increasingly, diagnostics companies are embedded within drug development programs from early-stage trials rather than entering the process later as companion diagnostic developers.
Historically, biomarkers were frequently validated only after a therapy demonstrated clinical benefit. Today, pharmaceutical developers often incorporate biomarker analysis earlier in clinical studies to better understand mechanism of action, identify responsive patient populations, and refine future trial design.
Liquid biopsy platforms have become especially attractive in this context because they allow repeated sampling over time. Tissue biopsies, while still considered the gold standard for many analyses, can be invasive and difficult to repeat at multiple points during a clinical trial.
By contrast, blood-based diagnostics allow longitudinal monitoring of tumor evolution, immune signaling, and treatment response. This capability is particularly valuable when testing drugs that attempt to reprogram immune activity rather than directly killing tumor cells.
Why PD-L1 dynamics could become a key indicator in CCR5-targeted immunotherapy strategies
One of the central hypotheses underlying the trial is that CCR5 blockade may alter the tumor immune environment in ways that increase PD-L1 expression. Earlier clinical observations in metastatic breast cancer suggested that leronlimab treatment was associated with increased PD-L1 expression in circulating tumor cells.
If similar patterns emerge in colorectal cancer, it could provide a mechanistic explanation for how CCR5 inhibition might sensitize tumors to immune-based therapies. Clinicians tracking the field often note that PD-L1 expression alone has proven an imperfect biomarker in many cancers. However, dynamic changes in PD-L1 during treatment may provide more useful insights than baseline measurements alone.
In the CytoDyn study, serial monitoring of PD-L1 through LifeTracDx may help determine whether immune signaling pathways are being activated during therapy. This information could guide future combination strategies involving checkpoint inhibitors or other immune modulators.
Such insights may prove particularly valuable for microsatellite-stable colorectal cancer, which represents the majority of metastatic colorectal cancer cases but remains resistant to many immunotherapy approaches currently used in other tumor types.
What the trial design reveals about the continuing search for effective therapies in refractory colorectal cancer
The Phase 2 trial evaluates leronlimab in combination with trifluridine and tipiracil, a chemotherapy agent commonly used in heavily pretreated colorectal cancer, along with bevacizumab, an anti-angiogenic monoclonal antibody. This combination reflects a broader trend toward multi-mechanism treatment strategies for advanced cancers.
Trifluridine and tipiracil provides cytotoxic activity that can suppress tumor growth, while bevacizumab targets vascular endothelial growth factor to limit tumor blood supply. Adding leronlimab introduces an immunomodulatory element that could theoretically reshape the tumor microenvironment.
The study’s primary endpoint is objective response rate measured using RECIST version 1.1 criteria over a 12-month treatment period. Secondary analyses will likely examine biomarker correlations and progression outcomes, though the exploratory biomarker analysis involving LifeTracDx is not a formal efficacy endpoint.
Industry analysts note that early-phase oncology trials increasingly incorporate such exploratory biomarker programs. While they may not determine regulatory approval directly, they often inform subsequent clinical strategies and companion diagnostic development.
Why circulating tumor cell technologies remain both promising and controversial in oncology diagnostics
Despite growing enthusiasm for liquid biopsy platforms, circulating tumor cell technologies have faced skepticism over the past decade. Some early-generation systems struggled with sensitivity and reproducibility, limiting their clinical adoption.
However, technological advances have gradually improved detection methods, allowing researchers to capture extremely rare tumor-derived cells in the bloodstream. Newer platforms attempt to combine multiple cell types or molecular signals to increase reliability.
Creatv Bio’s LifeTracDx approach, which incorporates both circulating tumor cells and cancer-associated macrophage-like cells, represents one attempt to expand the range of biological signals captured in blood samples. By monitoring immune-related markers such as PD-L1 and CCR5 expression, the test aims to reflect changes occurring within the tumor microenvironment.
Regulatory watchers note that the clinical utility of such diagnostics will ultimately depend on demonstrating that biomarker signals meaningfully correlate with treatment outcomes. Without clear predictive value, liquid biopsy platforms may remain primarily research tools rather than routine clinical tests.
What clinicians, regulators, and industry observers will watch as the trial progresses
Several questions remain unanswered as the CytoDyn study moves forward. One key issue is whether PD-L1 changes detected in circulating tumor cells truly correlate with improved clinical outcomes. If PD-L1 upregulation occurs without corresponding tumor response, the biomarker may have limited predictive value.
Another uncertainty involves the broader clinical viability of CCR5 inhibition in oncology. While the receptor has long been studied in immunology and infectious diseases, its role in cancer therapy remains under active investigation.
Clinicians tracking immunotherapy development will also be interested in whether combining CCR5 blockade with existing chemotherapy and anti-angiogenic agents produces measurable improvements over standard treatment regimens. Many prior attempts to convert immunologically cold tumors into responsive ones have produced mixed results.
For Creatv Bio, the collaboration represents an opportunity to demonstrate the utility of LifeTracDx in a prospective clinical trial setting. Success could strengthen the case for broader use of liquid biopsy biomarkers in oncology drug development.
For CytoDyn, the biomarker data could help clarify the biological effects of leronlimab and potentially guide future clinical strategies. In an increasingly crowded immunotherapy landscape, demonstrating clear mechanistic insights may prove as important as clinical outcomes themselves.
Ultimately, the collaboration highlights how oncology innovation is increasingly shaped by the intersection of therapeutics and diagnostics. As cancer treatment becomes more personalized and immune-driven, the ability to monitor tumor biology in real time may become one of the most valuable tools in clinical research.
How Creatv Bio’s LifeTracDx may change immune biomarker tracking in colorectal cancer studies added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →